巴西血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。II：CD19+急性淋巴细胞白血病患者的嵌合抗原受体T细胞疗法。
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.
作者信息
Seber Adriana, de CastroJunior Claudio Galvão, Kerbauy Lucila N, Hirayama Alexandre V, Bonfim Carmem, Fernandes Juliana Folloni, Souza Mair, Schafell Rony, Nabhan Samir, Loggetto Sandra Regina, Simões Belinda Pinto, Rocha Vanderson, de Lima Marcos, Guerino-Cunha Renato L, Bittencourt Henrique
机构信息
Hospital Samaritano Higienópolis, São Paulo, SP, Brazil; Hospital Infantil Sabará, São Paulo, SP, Brazil.
Hemomed Instituto de Oncologia e Hematologia, São Paulo, SP, Brazil; Hospital São Camilo, São Paulo, SP, Brazil.
出版信息
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S13-S21. doi: 10.1016/j.htct.2021.09.002.
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.
摘要
嵌合抗原受体T（CAR-T）细胞疗法是治疗急性淋巴细胞白血病（ALL）的一种新型治疗方式，对难治性或复发性疾病患者疗效显著。同时，CAR-T细胞疗法会引发独特且可能致命的毒性反应，如细胞因子释放综合征（CRS）和神经毒性（ICANS）。本文旨在就血液肿瘤学和细胞治疗领域的专家共识，针对目前在ALL患者中使用CAR-T细胞的情况提出建议。
相似文献
1
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.巴西血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。II：CD19+急性淋巴细胞白血病患者的嵌合抗原受体T细胞疗法。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S13-S21. doi: 10.1016/j.htct.2021.09.002.
2
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients.巴西血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。一：构建CAR-T细胞治疗患者多学科临床管理中心。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S3-S12. doi: 10.1016/j.htct.2021.09.001.
3
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.巴西血液学、血液治疗与细胞治疗协会 转基因细胞共识。III：非霍奇金淋巴瘤患者的抗CD19嵌合抗原受体T细胞疗法
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S22-S29. doi: 10.1016/j.htct.2021.09.003.
4
Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors.巴西血液学、血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。综述文章：实体瘤中的细胞治疗。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S78-S83. doi: 10.1016/j.htct.2021.09.011.
5
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation.巴西血液学、血液治疗与细胞治疗协会 转基因细胞共识。VIII：嵌合抗原受体T细胞：临床前开发 - 安全性与疗效评估。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S54-S63. doi: 10.1016/j.htct.2021.09.008.
6
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control.巴西血液学、血液治疗与细胞治疗协会 转基因细胞共识。第五章：生产与质量控制。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S35-S41. doi: 10.1016/j.htct.2021.09.005.
7
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients.巴西血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。IV：多发性骨髓瘤患者的嵌合抗原受体T细胞疗法
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S30-S34. doi: 10.1016/j.htct.2021.09.004.
8
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies.巴西血液学、血液治疗与细胞治疗协会 转基因细胞共识。VII. 嵌合抗原受体（CAR）细胞疗法生产技术的现状与未来。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S46-S53. doi: 10.1016/j.htct.2021.09.007.
9
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Special article: compassionate use and clinical trial on CAR-T cells.巴西血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。专题文章：CAR-T细胞的同情用药与临床试验。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S64-S67. doi: 10.1016/j.htct.2021.09.009.
10
Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.急性髓系白血病治疗指南：巴西血液学、血液疗法和细胞治疗协会：项目指南：巴西医学协会 - 2015年
Rev Bras Hematol Hemoter. 2016 Jan-Feb;38(1):58-74. doi: 10.1016/j.bjhh.2016.01.001. Epub 2016 Feb 5.
本文引用的文献
1
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients.巴西血液学、血液治疗与细胞治疗协会关于基因改造细胞的共识。一：构建CAR-T细胞治疗患者多学科临床管理中心。
Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S3-S12. doi: 10.1016/j.htct.2021.09.001.
2
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.泽沃基奥仑赛注射液（KTE-X19）治疗复发或难治性成人 B 细胞急性淋巴细胞白血病：ZUMA-3 研究单臂、开放标签、多中心的 2 期结果。
Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4.
3
Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.替沙格赛定用于治疗复发/难治性B细胞急性淋巴细胞白血病的儿童和年轻成人。
Pediatr Blood Cancer. 2021 Sep;68(9):e29123. doi: 10.1002/pbc.29123. Epub 2021 Jun 1.
4
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.tisagenlecleucel 治疗 B 细胞急性淋巴细胞白血病后 CD19 阳性与 CD19 阴性复发的决定因素。
Leukemia. 2021 Dec;35(12):3383-3393. doi: 10.1038/s41375-021-01281-7. Epub 2021 May 17.
5
An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia.CD19“CAR”-T 细胞疗法治疗儿童和青年 B 细胞急性淋巴细胞白血病的操作手册。
Blood Rev. 2021 Nov;50:100848. doi: 10.1016/j.blre.2021.100848. Epub 2021 May 6.
6
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.儿童和青少年 B 细胞急性淋巴细胞白血病患者接受 CD19-CAR T 细胞治疗的长期随访。
J Clin Oncol. 2021 May 20;39(15):1650-1659. doi: 10.1200/JCO.20.02262. Epub 2021 Mar 25.
7
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.桥接化疗对成人急性淋巴细胞白血病中CD19嵌合抗原受体T细胞疗法临床结局的影响
Leukemia. 2021 Nov;35(11):3268-3271. doi: 10.1038/s41375-021-01196-3. Epub 2021 Mar 8.
8
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 与化疗治疗高危初发 B 细胞急性淋巴细胞白血病患儿无事件生存的效果：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987.
9
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 巩固化疗后与化疗对初发 B 细胞急性淋巴细胞白血病儿童、青少年和年轻成人患者无病生存的影响：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669.
10
CAR T cells better than BiTEs.嵌合抗原受体T细胞比双特异性T细胞衔接器更好。
Blood Adv. 2021 Jan 26;5(2):602-606. doi: 10.1182/bloodadvances.2020003554.
Zotero 插件